Share buy-back programs often lead to an increase in stock prices as they reduce the number of shares outstanding, potentially increasing earnings per share and signaling company confidence to investors. Given the substantial amount of DKK3.5 billion, this program is likely to be viewed positively by the market, especially for a company like Genmab.